标题
Targeting adenosine for cancer immunotherapy
作者
关键词
Adenosine, A2a receptor, Checkpoint blockade, PD-1, Immunotherapy, CD39, CD73, CTLA-4
出版物
Journal for ImmunoTherapy of Cancer
Volume 6, Issue 1, Pages -
出版商
Springer Nature
发表日期
2018-06-18
DOI
10.1186/s40425-018-0360-8
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets
- (2017) Bertrand Allard et al. IMMUNOLOGICAL REVIEWS
- Targeting A2 adenosine receptors in cancer
- (2017) David Allard et al. IMMUNOLOGY AND CELL BIOLOGY
- Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
- (2017) Paul A. Beavis et al. JOURNAL OF CLINICAL INVESTIGATION
- Antigen spread (AgS) after sipuleucel-T (sip-T): A cross-trial comparison of 4 sip-T clinical trials of patients (pts) with prostate cancer (PC).
- (2017) Lawrence Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
- (2017) Silvana Morello et al. Journal of Translational Medicine
- Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease
- (2017) Fabrizio Stocchi et al. NEUROLOGY
- CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer
- (2017) Jieyao Li et al. OncoImmunology
- Overexpression of CD39 in hepatocellular carcinoma is an independent indicator of poor outcome after radical resection
- (2016) Xiao-Yan Cai et al. MEDICINE
- High expression of CD39 in gastric cancer reduces patient outcome following radical resection
- (2016) Xiao-Yan Cai et al. Oncology Letters
- A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
- (2016) Akio Ohta Frontiers in Immunology
- CD73-adenosine reduces immune responses and survival in ovarian cancer patients
- (2016) Pierre-Olivier Gaudreau et al. OncoImmunology
- Targeting CD73 in the tumor microenvironment with MEDI9447
- (2016) Carl M. Hay et al. OncoImmunology
- Something in the Air: Hyperoxic Conditioning of the Tumor Microenvironment for Enhanced Immunotherapy
- (2015) Robert D. Leone et al. CANCER CELL
- CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer
- (2015) B. G. Leclerc et al. CLINICAL CANCER RESEARCH
- CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer
- (2015) Marian S. Wettstein et al. DISEASE MARKERS
- Loss of CD73-mediated actin polymerization promotes endometrial tumor progression
- (2015) Jessica L. Bowser et al. JOURNAL OF CLINICAL INVESTIGATION
- The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment
- (2015) G. K. Pennock et al. ONCOLOGIST
- Allosteric interactions between agonists and antagonists within the adenosine A2Areceptor-dopamine D2receptor heterotetramer
- (2015) Jordi Bonaventura et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunological mechanisms of the antitumor effects of supplemental oxygenation
- (2015) Stephen M. Hatfield et al. Science Translational Medicine
- CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression
- (2015) Nathalie Bonnefoy et al. OncoImmunology
- Adenosine A2A Receptors Intrinsically Regulate CD8+ T Cells in the Tumor Microenvironment
- (2014) C. Cekic et al. CANCER RESEARCH
- Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor
- (2014) D. Mittal et al. CANCER RESEARCH
- Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance)
- (2014) S. M. Cushman et al. CLINICAL CANCER RESEARCH
- Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued
- (2014) Annalisa Pinna CNS DRUGS
- Targeting Cancer-Derived Adenosine:New Therapeutic Approaches
- (2014) A. Young et al. Cancer Discovery
- Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity
- (2014) J. Bastid et al. Cancer Immunology Research
- Hostile, Hypoxia-A2-Adenosinergic Tumor Biology as the Next Barrier to Overcome for Tumor Immunologists
- (2014) M. V. Sitkovsky et al. Cancer Immunology Research
- Extracellular adenosine regulates naive T cell development and peripheral maintenance
- (2013) Caglar Cekic et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Anti-Human CD73 Monoclonal Antibody Inhibits Metastasis Formation in Human Breast Cancer by Inducing Clustering and Internalization of CD73 Expressed on the Surface of Cancer Cells
- (2013) M. G. Terp et al. JOURNAL OF IMMUNOLOGY
- IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39
- (2013) Ivan D Mascanfroni et al. NATURE IMMUNOLOGY
- CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
- (2013) S. Loi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Blockade of A2Areceptors potently suppresses the metastasis of CD73+tumors
- (2013) Paul A. Beavis et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma
- (2013) Xiao-Xia Lu WORLD JOURNAL OF GASTROENTEROLOGY
- Increased CD39 expression on CD4+ T lymphocytes has clinical and prognostic significance in chronic lymphocytic leukemia
- (2012) Chava Perry et al. ANNALS OF HEMATOLOGY
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- CD73-Deficient Mice Are Resistant to Carcinogenesis
- (2012) J. Stagg et al. CANCER RESEARCH
- Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer inCd39/Entpd1null Mice
- (2012) Xiaofeng Sun et al. HEPATOLOGY
- High expression of CD73 as a poor prognostic biomarker in human colorectal cancer
- (2012) Xian-Rui Wu et al. JOURNAL OF SURGICAL ONCOLOGY
- Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor
- (2011) Adam T. Waickman et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis
- (2011) J. Stagg et al. CANCER RESEARCH
- CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice
- (2011) Long Wang et al. JOURNAL OF CLINICAL INVESTIGATION
- Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer
- (2011) Beat M. Künzli et al. Purinergic Signalling
- CD73 Expression as a Potential Marker of Good Prognosis in Breast Carcinoma
- (2011) Anna Supernat et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- CD39/ENTPD1 Expression by CD4+Foxp3+ Regulatory T Cells Promotes Hepatic Metastatic Tumor Growth in Mice
- (2010) Xiaofeng Sun et al. GASTROENTEROLOGY
- Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
- (2010) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Adenosine regulates CD8 T-cell priming by inhibition of membrane-proximal T-cell receptor signalling
- (2009) Carsten Linnemann et al. IMMUNOLOGY
- Human Follicular Lymphoma CD39+-Infiltrating T Cells Contribute to Adenosine-Mediated T Cell Hyporesponsiveness
- (2009) S. P. Hilchey et al. JOURNAL OF IMMUNOLOGY
- Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial
- (2009) H.H. Fernandez et al. PARKINSONISM & RELATED DISORDERS
- Adenosine receptors in regulation of dendritic cell differentiation and function
- (2008) S. V. Novitskiy et al. BLOOD
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started